24. Quality of Life after the Diagnosis of Hematological Malignancies

  1. Hussain I. Saba MD, PHD2 and
  2. Ghulam J. Mufti MB, DM, FRCP, FRCPATH3
  1. Mohamed Sorror MD, MSc

Published Online: 24 MAR 2011

DOI: 10.1002/9781444394016.ch24

Advances in Malignant Hematology

Advances in Malignant Hematology

How to Cite

Sorror, M. (2011) Quality of Life after the Diagnosis of Hematological Malignancies, in Advances in Malignant Hematology (eds H. I. Saba and G. J. Mufti), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444394016.ch24

Editor Information

  1. 2

    James A. Haley Veterans' Hospital, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL, USA

  2. 3

    Department of Haematological Medicine, Guy's and St Thomas' School of Medicine, King's College Hospital, London, UK

Author Information

  1. Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA

Publication History

  1. Published Online: 24 MAR 2011
  2. Published Print: 16 APR 2011

ISBN Information

Print ISBN: 9781405196260

Online ISBN: 9781444394016



  • hematological malignancies;
  • quality of life;
  • acute leukemia;
  • chronic leukemia;
  • lymphoma;
  • autologous;
  • allogeneic;
  • hematopoietic cell transplantation


For years, the main goal of investigators and clinicians in the field of hematological malignancies (HM) has been cure. On the other hand, our patients hoped for both cure and good quality of life (QOL). Great advances have been made in creating novel conventional treatments of HM and in optimizing benefits from hematopoietic cell transplantation (HCT). With these advances, excellence in QOL is becoming one of the goals of treatment and an essential end point to measure success of interventions. QOL among survivors of HM are reviewed in this chapter. First, QOL among different HM are described following conventional chemo/radiotherapy. Second, the impacts of autologous and allogeneic HCT on QOL are discussed. Third, patterns of QOL are compared after conventional, autologous, and allogeneic HCT. Finally, emphasis is focused on the remaining problems to advance QOL research and applicability in clinical practice in addition to possible interventions to further improve QOL.